A peptide Certificate of Analysis (CoA) is a results document for a defined sample and test scope. It may report identity, chromatographic purity, quantity or other measurements, but those terms are not interchangeable. A useful reading begins with traceability—what was tested and which batch it represents—then moves to the method, result, units and acceptance criteria.
Research-use notice: This article is for general laboratory education. Helix Bio products are supplied strictly for research purposes only and are not intended for human or veterinary use, consumption, diagnosis, treatment or any clinical application. A CoA does not change that designation and is not medical or safety advice.
If you are looking for Helix Bio’s available batch documents, use the Certificates of Analysis library. For definitions of unfamiliar terms, keep the peptide research glossary open alongside the report.
What is a Certificate of Analysis?
A CoA records the results of specified analytical work performed on a sample. Depending on the commissioned scope, it can identify the submitted material, list the method used, report numerical or qualitative findings, show an acceptance criterion and state whether the sample met that criterion.
The title “Certificate of Analysis” should not be read as “regulatory certificate.” It does not automatically certify the supplier, approve the manufacturing facility or establish that the material is suitable for every possible application. Its evidential value depends on the report’s traceability, methods, data and limitations.
Formal pharmaceutical guidance helps explain the underlying analytical principles, even though a research-use-only material is not the same thing as an approved medicine. ICH Q6A defines a specification as a set of tests, referenced procedures and acceptance criteria; it also stresses that specifications are only one part of a wider control strategy. ICH Q2(R2) says an analytical procedure should be shown to be fit for its intended purpose. Those ideas lead to the two best questions to ask of any result: what exactly was measured, and was the method suitable for that measurement?
How to read a peptide CoA: the six-point check
1. Identify the sample
Start with the product or sample name, description and any stated strength. Check spelling, peptide form and relevant modification because similar names do not necessarily describe the same molecule. If a molecular formula, sequence or expected molecular mass is shown, treat it as identifying information to compare with the laboratory result—not as proof by itself.
Then compare the report with the product page or label. For example, a document intended to support a Retatrutide batch should not be silently applied to Semaglutide, and a report for one listed strength should not be assumed to cover another unless the documentation makes that connection clear.
2. Match the batch or lot number
A batch or lot identifier connects the report with a defined group of material. Compare the identifier on the CoA with the vial label and receiving records character by character. A product-level report with no batch identifier may still describe useful analytical work, but it provides weaker traceability than a document that clearly matches the material in hand.
Do not treat a result from an earlier batch as proof for a later one. The same named peptide can be produced in multiple batches, and the analytical result applies to the sample described in the report. Record any mismatch or missing identifier instead of filling the gap by assumption.
3. Check the laboratory and dates
Look for the reporting laboratory, report number, sample-receipt or test date, issue date and an authorised review or approval field where applicable. Dates help establish when the work occurred and whether the report plausibly relates to the batch’s production and release timeline.
Laboratory accreditation, if claimed, should be checked separately against the accrediting body’s directory and the laboratory’s scope. Accreditation of an organisation does not mean every conceivable test is included in its accredited scope. Equally, a logo or digital signature does not replace the need to examine the actual method, result and sample match.
4. Read the test method—not just the headline result
The method determines what a number means. “HPLC,” “LC–MS” or “MS” alone may be only a broad technique label. A stronger report identifies the procedure or enough method context to understand the measurement. Relevant details can include the analytical mode, detector, reference material, calculation basis and whether the value is an area percentage, mass measurement or calibrated quantitative result.
ICH Q2(R2) highlights performance characteristics such as specificity or selectivity, accuracy, precision and reportable range. It also notes that more than one procedure may be needed where a single method lacks sufficient discrimination. A compact CoA will not necessarily contain the full validation package, but the reader should avoid assuming that every method answers every question.
5. Separate the result from the acceptance criterion
The result is what the laboratory measured. The acceptance criterion is the limit, range or qualitative requirement used to judge that result. A report may show both, or it may provide a result without stating a specification. “Pass” has little context unless the document identifies what was tested and the criterion against which it passed.
Read the units and comparison signs carefully. “Not detected,” “below the reporting limit” and “zero” are not the same statement. Likewise, a percentage requires a basis: chromatographic peak area, assay against a reference standard and weight fraction are different measurements. Never add a percentage to a vial label or product claim unless the underlying report supports that exact interpretation.
6. Read notes, attachments and limitations
Footnotes can define abbreviations, calculation rules, uncertainty, detection limits, sample condition or deviations. Attachments may contain the chromatogram, spectrum or other output that supports the summary table. Check whether the report refers to pages that are absent and whether the sample was submitted by the customer rather than independently collected by the laboratory.
That last distinction matters. A laboratory can accurately analyse the sample it receives, but the report alone may not prove who selected the sample or how representative it was of the wider batch. Traceability is a chain, not a single PDF.
HPLC purity: what the percentage can and cannot mean
High-performance liquid chromatography separates detectable components under defined conditions. In peptide analysis, a chromatogram commonly shows peaks over retention time. A calculated area percentage can describe how much of the detected chromatographic signal is associated with the main peak relative to other integrated peaks under that method.
That can be useful evidence of chromatographic purity, but it is not automatically the total mass of peptide in a vial. The calculation may not count substances that do not respond to the detector in the same way, and its meaning depends on sample preparation, detector response, integration rules and the separation achieved. Water, salts, counterions or other non-detected material may not be represented by the headline area percentage.
For the same reason, “99% HPLC purity” should not be translated into “99% of the vial is active peptide” without an appropriate quantitative assay and calculation basis. ICH Q6A distinguishes identification, assay and impurity testing, while recognising that one validated procedure can sometimes support more than one purpose. The report must show which purpose the method served.
Mass spectrometry: evidence about molecular identity
Mass spectrometry measures ions by their mass-to-charge ratio. For a peptide, the observed spectrum can be compared with the expected molecular mass and expected charge states. A matching result can support an identity assessment, especially when combined with chromatographic separation or another appropriately selective technique.
It does not follow that a matching mass establishes chromatographic purity, exact vial content, sterility or biological activity. Closely related structures, modifications, fragments or adducts can require careful interpretation. ICH Q2(R2) describes identity as demonstrating the capability to identify the analyte through unique structural or other specific properties, and it recognises orthogonal procedures—methods based on different measurement principles—as a way to strengthen specificity.
LC–MS combines liquid-chromatographic separation with mass detection. This can place separation and mass information in the same workflow, but the conclusion is still limited to the method, sample and data reported.
Quantity, net content and assay are separate questions
A label strength and an HPLC area percentage do not together establish how much peptide is present. A quantitative content or assay result needs an appropriate calibrated method, reference standard and stated calculation basis. The report should make clear whether the value refers to peptide content, total lyophilised material, concentration in a prepared test solution or another measurement.
This is particularly important for lyophilised materials, where the visible cake or film is not a reliable measure of quantity. Excipients, residual moisture, salts and the physical distribution of a small mass can affect appearance. For background on the physical state, read what lyophilised means and how freeze-drying works.
Traceability: can the report be connected to the material?
A credible reading follows the chain from product name to batch or lot, from batch to submitted sample, and from sample ID to final report. Useful records can include the label, order or receipt record, batch identifier, laboratory submission reference, report number and archived document.
When reviewing Helix Bio documentation, compare the CoA with the applicable product listing—such as GHK-Cu—and use the CoA library to see the current report status. The wider research peptide collection provides the currently listed strengths and research-use information.
Good documentation also preserves the original report rather than relying on a cropped screenshot. FDA data-integrity guidance, written for regulated CGMP records, defines data integrity in terms of completeness, consistency and accuracy and uses the ALCOA principles: attributable, legible, contemporaneously recorded, original or a true copy, and accurate. Although that guidance applies in a specific regulatory context, the record-keeping principle is broadly useful: retain enough context to understand where the result came from and what changed, if anything.
What a peptide CoA does not prove
A CoA only reports work within its stated scope. Unless the relevant test was performed and reported, do not infer:
- Sterility: chromatographic purity or a mass match is not a sterility test.
- Endotoxin level: endotoxin requires its own appropriate test and stated result.
- Microbial quality: identity testing does not establish the absence of microorganisms.
- Residual solvents, water or counterion content: these require relevant methods if they matter to the specification.
- Stability over time: one release result is not a stability programme or universal shelf-life claim.
- Fitness for a particular experiment: the receiving laboratory must evaluate the material against its own validated protocol and risk assessment.
- Suitability for human or veterinary use: a research-material CoA is not marketing authorisation, clinical approval or evidence of safe administration.
Storage is also a separate control. A satisfactory report does not protect a sample from later exposure to unsuitable temperature, moisture, light or repeated temperature cycling. Read the peptide storage and stability guide, while giving priority to the label and batch-specific documentation.
A practical one-minute CoA checklist
- Does the product or sample name match?
- Does the batch or lot number match the label and records?
- Are the laboratory, report number and dates identifiable?
- Is each reported result tied to a named method?
- Are the units and calculation basis clear?
- Is an acceptance criterion stated, and is “pass” traceable to it?
- Are chromatographic purity, identity and quantity kept separate?
- Are the pages, attachments and stated limitations complete?
- Have you avoided inferring tests that were not performed?
- Can the original document be retained with the laboratory record?
Frequently asked questions
Does a high HPLC purity percentage prove the vial contains the labelled amount?
No. Chromatographic purity and quantitative content answer different questions. A separate suitable assay may be required to determine how much peptide is present.
Is mass spectrometry enough to prove purity?
No. A mass result can support identity by comparing observed mass-to-charge information with expected data. Purity requires an appropriate impurity or separation assessment, and quantity requires an appropriate quantitative method.
Does a CoA mean a peptide is approved or certified by a regulator?
No. A CoA reports specified analytical results for the sample described. It is not, by itself, approval of the product, supplier, facility or intended use.
Why does the batch number matter?
It connects the report to a defined group of material. Without a reliable match, a result can be mistakenly applied to a different batch that was not represented by the tested sample.
Should a chromatogram or spectrum be attached?
Supporting output can make the report easier to assess because it shows the data behind the summary. Its absence does not automatically invalidate a report, but the reader should understand what evidence was supplied and what remains unavailable.
The responsible conclusion
A strong CoA review does not stop at the largest percentage on the page. It confirms the sample and batch, identifies the laboratory and dates, reads the method, separates result from acceptance criterion, checks the units and keeps purity, identity and quantity distinct. Most importantly, it treats untested attributes as unknown rather than implied.
For research purposes only — not for human consumption.
This article provides general educational information about analytical documentation. It does not provide dosing, administration, treatment or clinical-use guidance.
Sources and further reading
- ICH Q2(R2): Validation of Analytical Procedures, corrected version published by ICH.
- ICH Q6A: Specifications—Test Procedures and Acceptance Criteria.
- FDA: Data Integrity and Compliance With Drug CGMP—Questions and Answers.
Last reviewed: 21 September 2026.